Compare NNNN & WEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNNN | WEN |
|---|---|---|
| Founded | 2021 | 1969 |
| Country | Germany | United States |
| Employees | 27 | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | N/A | 2000 |
| Metric | NNNN | WEN |
|---|---|---|
| Price | $16.79 | $6.87 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 22 |
| Target Price | N/A | ★ $8.84 |
| AVG Volume (30 Days) | 21.2K | ★ 8.3M |
| Earning Date | 04-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 8.28% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.12 |
| Revenue | N/A | ★ $2,176,891,000.00 |
| Revenue This Year | N/A | $2.26 |
| Revenue Next Year | N/A | $0.94 |
| P/E Ratio | $446.57 | ★ $57.83 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.50 | $6.37 |
| 52 Week High | $55.65 | $12.51 |
| Indicator | NNNN | WEN |
|---|---|---|
| Relative Strength Index (RSI) | 33.36 | 44.84 |
| Support Level | $14.66 | $6.62 |
| Resistance Level | $31.12 | $7.28 |
| Average True Range (ATR) | 3.11 | 0.31 |
| MACD | -0.97 | -0.02 |
| Stochastic Oscillator | 9.95 | 25.56 |
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
The Wendy's Co is engaged in operating, developing, and franchising a system of distinctive quick-service restaurants serving high-quality food. The company operates through Wendy's U.S., Wendy's International, and Global Real Estate & Development. Wendy's U.S. and Wendy's International include the operation and franchising of restaurants and derive revenues from sales at company-operated restaurants, as well as royalties, franchise fees, and advertising fund collections from franchised restaurants. Global Real Estate & Development includes real estate activities for owned and leased sites that are leased or subleased to franchisees and includes the company's share of income from its Canadian restaurant real estate joint venture.